What are the pharmaceutical and health stocks in 2023?

What are the sector leaders in biopharmaceutical stocks? Let’s take a look.

First, let’s take a look at the leading stocks in the biopharmaceutical sector: Hengrui Pharmaceuticals, Mindray Medical, WuXi AppTec, Changchun High-tech, Zhifei Biotech, Hualan Biotech, Fosun Pharma, and Aier Ophthalmology.

Below, the editor brings 2023 pharmaceutical and health stocks. Let’s take a look together. I hope it can bring reference.

What are the leading stocks in biopharmaceutical stocks? 1. Hengrui Pharmaceutical (600276), the first domestic innovative drug stock.

The main product lines include anti-tumor, anesthesia, contrast agents, etc.

The company's return on net assets has remained above 23% for many years, and its net profit has maintained a growth rate of more than 20% for many years.

The company has very strong R&D capabilities, an excellent management team, and strong sales capabilities.

2. Aier Eye Hospital (300015), the No. 1 ophthalmology hospital chain in China.

It mainly provides patients with ophthalmic medical services such as diagnosis and treatment of various eye diseases, as well as medical optometry and glasses.

The company's return on net assets has remained around 20% for many years, and its net profit has maintained a growth rate of over 30% for many years.

The company's business model is relatively excellent, and its operating capabilities and brand reputation continue to increase.

3. Mindray Medical (300760), the first domestic medical device stock.

The main product lines include life and information support, in vitro diagnosis, medical imaging, etc.

The company's return on net assets has remained above 25% for many years, and its net profit has maintained a growth rate of more than 25% for many years.

As a leader in medical devices that has completed its global layout, the company has steadily advanced towards high-end and platform-based products. Its position is very solid and its long-term space is huge.

4. Changchun High-tech (000661), the first domestic biopharmaceutical stock.

The main product lines include growth hormone, syncytial virus vaccine, etc.

The company's return on net assets has remained above 16% for many years, and its net profit has maintained a growth rate of more than 30% for many years.

As my country's leading biopharmaceutical company, the company's performance has exceeded expectations.

5. WuXi AppTec (603259), the first domestic medical R&D services company.

The main business is the all-round, integrated platform service for the discovery, development and production of small molecule chemical drugs.

The company's return on net assets has remained above 20% for many years, and its net profit has maintained a growth rate of more than 25% for many years.

The company is the world's leading pharmaceutical R&D service platform with a vast market space and its performance is expected to maintain rapid growth.

6. Tigermed (300347), the leading clinical contract research organization (CRO) in China.

The main business is to provide clinical research services such as phase I to IV clinical trial technical services and data management for pharmaceutical product research and development.

The company's return on net assets has increased to about 17% in the past two years, and its net profit has maintained a growth rate of more than 56% for many years.

7. Wowu Biology (300357), the first domestic desensitization diagnosis and treatment company.

The company's dust mite drops have maintained rapid growth, and its blockbuster product, Artemisia annua pollen sublingual drops, has entered on-site inspection and is expected to be approved for marketing in 2020.

The company's return on net assets has remained above 21% for many years, and its net profit has maintained a growth rate of more than 25% for many years.

As the only leading sublingual desensitization company in my country, the company has an excellent competitive landscape with a market share of over 80%. The company has great long-term growth potential.

8. Tongce Medical (600763), the first domestic dental chain.

The company has launched a dental hospital chain layout through the "hospital replicable + doctor replicable + team replicable" model.

The company's return on net assets has remained around 23% for many years, and its net profit has maintained a growth rate of around 50% for many years.

my country's dental market has vast space, and the company is expected to achieve rapid development under the two major trends of population aging and consumption upgrading.

9. Antu Biotech (603658), the leading domestic IVD stock.

The company is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments.

The company's return on net assets has remained around 30% for many years, and its net profit has maintained a growth rate of more than 25% for many years.

The chemiluminescence industry will enter an era of differentiation.

With the advantages of 70% biological raw material assets, mainstream projects, and assembly lines, the company is expected to continue to replace foreign-funded and other domestic-funded products and maintain sustained growth.

10. Hualan Biotechnology (002007), the leading domestic blood products stock.

The company's main product lines are blood products and vaccine products.

The company's return on net assets has remained around 19% for many years, and its net profit has maintained a growth rate of around 30% for many years.

As the domestic blood products industry slowly recovers and flu vaccines continue to increase in volume, the company's performance is expected to be further improved.

List of leading biopharmaceutical stocks On March 21, three pharmaceutical companies with a market value of over 100 billion announced their 2022 annual reports.

Among them, WuXi AppTec’s revenue reached a record high last year, and its net profit increased by 70%; Wantai Biologics, which specializes in vaccines and in vitro diagnostics, nearly doubled its revenue, and its net profit increased by more than 130%; another vaccine company, Zhifei Biologics

Net profit fell 26% year-on-year.